On-target off-tumor toxicity of CAR modified T cells was first reported in a phase I clinical trial of renal cell carcinoma patients treated with T cells expressing a CAR recognizing carbonic anhydrase IX (CAIX) [31]. This evidence concerns the gene CA9 and neoplasm.